ArticleNature2026
Nutrient requirements of organ-specific metastasis in breast cancer.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Physiological folate levels constrain nucleotide synthesis and increase dependence on nucleotide salvage.bioRxiv : the preprint server for biology · 2026Article
- Article
- Peritoneal ovarian cancer growth in the omentum proceeds independently of mature adipocytes.Nature communications · 2026Article
- Supplementation via DAF-16 andbioRxiv : the preprint server for biology · 2026Article
- Metabolic plasticity and optimal redox homeostasis are essential for efficient metastatic colonization.Molecular metabolism · 2026Article
- The metabolic plasticity of cancer stem cells: bidirectional crosstalk with organ-resident cells.Experimental & molecular medicine · 2026Review
- Metabolic networks in the tumor microenvironment: roles of amino acid and lipid metabolism pathways in cancer progression and therapy.Experimental & molecular medicine · 2026Review
- Mitochondrial transfer: a new perspective on tumor-microenvironment crosstalk driving metastasis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Keene L Abbott *Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6166-704X
Sonu Subudhi *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-5937-1880
Raphael Ferreira *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9881-6232
Yetiş GültekinDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sophie C SteinbuchSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Muhammad Bin MunimDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Diya L RameshDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0009-0009-4255-6967
Sophie E HonederKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-7201-6293
Ashwin S KumarBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Michelle WuDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0009-0001-8120-6072
Jacob A HansenDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Anna Shevzov-ZebrunDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Edrees H RashanDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Kian M EghbalianKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sharanya SivanandDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Anna M BarbeauDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-2382-4999
Lisa M RiedmayrDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0307-2507
Mark DuquetteSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Ahmed AliDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nicole HenningKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sonia E TrojanDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-8876-6294
Millenia WaiteKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Tenzin KunchokKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-6603-4607
Mayu A NakanoSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Florian GourgueDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-9777-806X
Gino B FerraroSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Brian T DoDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4992-2623
Virginia SpanoudakiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Francisco J Sánchez-RiveraDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-8466-8563
Xin JinWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China.ORCID 0000-0003-4167-1743
George M ChurchDepartment of Genetics, Harvard Medical School, Boston, MA, USA. gchurch@genetics.med.harvard.edu.ORCID 0000-0001-6232-9969
Rakesh K JainSteele Laboratories of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. rjain@mgh.harvard.edu.ORCID 0000-0001-7571-3548
Matthew G Vander HeidenDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. mvh@mit.edu.ORCID 0000-0002-6702-4192
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MPRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8MUnderstanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8MDissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7MTargeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1MReprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9MImproving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3MReengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2MReprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2R01NS118929 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2021 to 2025
$2.0MReprogramming the tumormicroenvironment to improve immunotherapy of glioblastomaR01CA269672 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Rakesh K. Jain · 2022 to 2026
$1.9MExploiting metabolic vulnerabilities of breast cancer brain metastases for therapyF31CA271787 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABBOTT, KEENE · 2022 to 2023
$94kNCI NIH HHS F31 CA271787NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA259253NCI NIH HHS R01 CA269672NCI NIH HHS R35 CA197743NCI NIH HHS R35 CA242379NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842NIGMS NIH HHS T32 GM007287NINDS NIH HHS R01 NS118929
Abstract
Cancer metastasis is a major contributor to patient morbidity and mortality
Indexed as
Breast NeoplasmsNeoplasm MetastasisNutrientsOrgan SpecificityAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceNucleotidesPurinesTumor MicroenvironmentNucleotidespurinePurines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.